GlassScriptPhysician profile
Hector R Pun
NPI 1447304944
$22,475.10
in general payments reported to CMS, 2019-2025
58 companies · $4,251 in 2025
The $4,251 reported for 2025 was more than what 90% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,005 · 2020: $2,188 · 2021: $3,224 · 2022: $3,108 · 2023: $3,578 · 2024: $3,123 · 2025: $4,251.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $11K · Education: $187.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,764.27 |
| Education | $187.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,407.06 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Glaxosmithkline, LLC. | $2,310.70 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Novo Nordisk INC | $1,925.43 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,870.37 | 2019-2025 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $1,526.29 | 2021-2025 | |
| Lilly USA, LLC | $1,406.19 | 2019-2025 | Jardiance, Mounjaro, Zepbound |
| Astellas Pharma US INC | $1,126.12 | 2019-2025 | Veozah, Myrbetriq |
| Merck Sharp & Dohme LLC | $1,018.82 | 2019-2025 | Verquvo, Lagevrio, Dificid |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $874.96 | 2019-2025 | Xifaxan, Trulance |
| Amgen INC. | $859.17 | 2019-2025 | Evenity, Otezla, Repatha |
| E.R. Squibb & Sons, L.L.C. | $799.71 | 2019-2025 | Eliquis, Camzyos |
| Pfizer INC. | $674.46 | 2019-2025 | |
| Amarin Pharma, INC. | $662.50 | 2019-2023 | |
| Abbvie INC. | $585.80 | 2020-2025 | |
| Janssen Pharmaceuticals, INC | $515.84 | 2019-2022 |
Show all 58 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hector Pun listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.